Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.